Key Takeaways
- • Railpen, which manages £36bn in assets for over 350,000 members, is leading the establishment of a £1bn+ Scale-up Fund alongside other UK pension providers (including NEST and Border to Coast Pensions Partnership) to invest in high-growth British science and technology companies.
- • The initiative is backed by the British Business Bank and the Office for Investment, addressing a structural gap in long-term, patient capital access for UK scale-up businesses despite strong domestic innovation capabilities.
- • The fund structure has been designed to balance pension fund fiduciaries' obligation to deliver strong risk-adjusted returns with government objectives around taxpayer value, after months of alignment work on objectives, challenges, and governance.
- • For long-term institutional investors like Railpen, high-growth company investments offer an attractive combination of return potential, liquidity characteristics, and portfolio diversification benefits alongside enhanced retirement outcomes for members.
Summary
Railpen, the industry-wide pension scheme managing approximately £36bn in assets on behalf of more than 350,000 members, has taken a leading role in establishing a dedicated £1bn+ Scale-up Fund designed to channel institutional capital toward UK high-growth science and technology companies. The initiative brings together multiple major UK pension providers—including NEST and Border to Coast Pensions Partnership—supported by the British Business Bank and the Office for Investment.
The fund addresses a well-documented constraint on UK growth companies: while the country generates world-class ideas, talent, and research through its universities and innovation ecosystem, many high-growth enterprises have historically struggled to access the long-term, patient capital required to scale domestically. According to Anna Rule of Railpen, this structural gap has been a consistent obstacle despite the UK's innovation strengths.
Railpen has been advocating for a dedicated Scale-up Fund since at least the prior year. The design phase involved months of collaborative work to align objectives between pension fund fiduciaries and government stakeholders, identify implementation challenges, and construct a governance framework that protects both pension members' retirement outcomes and taxpayer value. The fund structure remains under finalization as of the announcement date.
From the perspective of long-term institutional investors like Railpen, allocations to high-growth equity offer multiple portfolio benefits: return potential aligned with inflation and long-term liabilities, liquidity characteristics suited to patient capital strategies, and diversification advantages across asset classes. Rule emphasized that any innovation allocation—whether through venture capital, growth equity, or broader private market strategies—must demonstrate potential to enhance portfolio performance on a risk-adjusted basis, reflecting Railpen's primary fiduciary responsibility to members. The UK evidence supporting such allocations, according to the announcement, is "compelling," though specific return data or portfolio analysis was not detailed in the available materials.
The fund addresses a well-documented constraint on UK growth companies: while the country generates world-class ideas, talent, and research through its universities and innovation ecosystem, many high-growth enterprises have historically struggled to access the long-term, patient capital required to scale domestically. According to Anna Rule of Railpen, this structural gap has been a consistent obstacle despite the UK's innovation strengths.
Railpen has been advocating for a dedicated Scale-up Fund since at least the prior year. The design phase involved months of collaborative work to align objectives between pension fund fiduciaries and government stakeholders, identify implementation challenges, and construct a governance framework that protects both pension members' retirement outcomes and taxpayer value. The fund structure remains under finalization as of the announcement date.
From the perspective of long-term institutional investors like Railpen, allocations to high-growth equity offer multiple portfolio benefits: return potential aligned with inflation and long-term liabilities, liquidity characteristics suited to patient capital strategies, and diversification advantages across asset classes. Rule emphasized that any innovation allocation—whether through venture capital, growth equity, or broader private market strategies—must demonstrate potential to enhance portfolio performance on a risk-adjusted basis, reflecting Railpen's primary fiduciary responsibility to members. The UK evidence supporting such allocations, according to the announcement, is "compelling," though specific return data or portfolio analysis was not detailed in the available materials.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.